louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00048724: Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)
Official title: PEG-Intron as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects With Compensated Cirrhosis (METAVIR F4), Secondary to Chronic Hepatitis C, Who Have Failed to Respond to Therapy With Any Alpha Interferon Plus Ribavirin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chronic Hepatitis C
Cirrhosis
Keywords: Hepatitis C; Cirrhosis
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2002-11-08
Enrollment: 631
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no treatment for the prevention of disease progression in adult subjects with compensated cirrhosis secondary to chronic hepatitis C, who failed to respond to therapy with an a interferon plus ribavirin.


Eligibility criteria: Inclusion Criteria:

* Age at entry 18-65 years;
* Non-responders to previous treatment (minimum of 3 months) with an alpha interferon plus ribavirin;
* Liver biopsy demonstrating cirrhosis

Exclusion Criteria:

* Any other cause for liver disease other than chronic hepatitis C;
* History or presence of complications of cirrhosis;
* Alcohol or illicit drug abuse or treatment with methadone within the past 2 years;
* Diseases or conditions that could interfere with participation in the study

Primary outcomes:
measure: Time to Observation of the First Clinical Event Experienced by a Subject
timeFrame: Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event
Secondary outcomes:
measure: Time to Observation of the Disease Progression Experienced by a Subject
timeFrame: Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event
Other outcomes:
Locations:
Study officials:
References:
citation: Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, Berg T, Poo JL, Mello CB, Guenther R, Niederau C, Terg R, Bedossa P, Boparai N, Griffel LH, Burroughs M, Brass CA, Albrecht JK; EPIC3 Study Group. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011 Jun;140(7):1990-9. doi: 10.1053/j.gastro.2011.03.010. Epub 2011 Mar 17.
Clinical trial NCT00154024: Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.
Official title: Characterization of Local Vascular Effects of Angiotensin II and Histamine After Treatment With Irbesartan and Atorvastatin.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Subjects
Keywords: venoconstriction
venodilation
pleiotropic effects
Lead sponsor: Technische Universität Dresden
Sponsor class: OTHER
First posted: 2005-09-12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Vascular responses to angiotensin II and histamine are compared before and after 30 days of systemic treatment with either irbesartan 150 mg or atorvastatin 20 mg.

Detailed description: Vascular responses to angiotensin II and histamine are compared before and after 30 days of systemic treatment with either irbesartan 150 mg or atorvastatin 20 mg.

Eligibility criteria: Inclusion Criteria:

* healthy subjects
* no relevant disease
* amendment: hypercholesterolaemic subjects

Exclusion Criteria:

* any relevant disease

Primary outcomes:
measure: vascular responses after treatment.
Secondary outcomes:
Other outcomes:
Locations:
city: Dresden
country: Germany
facility: Institute of Clinical Pharmacology, Medical Faculty, University of Technology
Study officials:
affiliation: Institute of Clinical Pharmacology
name: Wilhelm Kirch, MD
role: STUDY_CHAIR
References:
citation: Schindler C, Guenther K, Hermann C, Ferrario CM, Schroeder C, Haufe S, Jordan J, Kirch W. Statin treatment in hypercholesterolemic men does not attenuate angiotensin II-induced venoconstriction. PLoS One. 2014 Sep 29;9(9):e103909. doi: 10.1371/journal.pone.0103909. eCollection 2014.
Clinical trial NCT00189124: Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention
Official title: Does DHEA Improve Endothelial Dysfunction and Other Cardiovascular Risk Factors in Premenopausal Women With Systemic Lupus?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Systemic Lupus Erythematosus
Keywords: Systemic Lupus Erythematosus
Dehydroepiandrosterone (DHEA)
DHEA
SLE
Lupus
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: Arthritis Foundation
First posted: 2005-09-16
Enrollment: 13
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of DHEA on endothelial dysfunction in patients with systemic lupus by measuring:

1. changes in brachial artery flow-mediated dilatation (FMD) and
2. changes in biomarkers of cardiovascular risk. Patients will be enrolled in a randomized, double-blinded crossover trial of DHEA or placebo for ten weeks, then crossed over to the alternate treatment arm after a six-week washout period.

HYPOTHESIS: Dehydroepiandrosterone (DHEA) administration in premenopausal women with SLE modifies cardiovascular risk by improving vascular endothelial function and other biomarkers associated with cardiovascular heart disease.


Eligibility criteria: Inclusion Criteria:

* Female
* Member of the Michigan Lupus Cohort
* Meet the American College of Rheumatology (ACR) criteria for SLE
* Premenopausal

Exclusion Criteria:

* Smoker
* Diabetic
* Prednisone dose \> 10 mg

Primary outcomes:
measure: Brachial artery reactivity, by flow mediated dilatation
Secondary outcomes:
measure: Changes in biomarkers of SLE
measure: Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Wendy Marder, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02006524: Screening for Silent Atrial Fibrillation During Influenza Vaccination
Official title: Screening for Silent Atrial Fibrillation During Influenza Vaccination
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atrial Fibrillation
Keywords: Silent atrial fibrillation
primary care
screening
influenza vaccination
Lead sponsor: UMC Utrecht
Sponsor class: OTHER
Collaborators: name: Boehringer Ingelheim
First posted: 2013-12-10
Enrollment: 3269
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Silent atrial fibrillation is an important cause of unnecessary strokes. If diagnosed and treated in time with anticoagulants, many disabling strokes can be prevented. In order to improve the diagnosis of atrial fibrillation the MyDiagnostick is developed; a user friendly and easy to use stick that diagnoses atrial fibrillation in one minute. During influenza vaccination, many patients who are also at risk for atrial fibrillation visit the general practice. This offers an ideal opportunity for screening for atrial fibrillation. The study investigates the yield of screening for atrial fibrillation with the MyDiagnostick during influenza vaccination (newly detected atrial fibrillation with corresponding CHA2DS2-Vasc score).


Eligibility criteria: Inclusion Criteria:

* Eligible for influenza vaccination

Exclusion Criteria:

* Not eligible for influenza vaccination

Primary outcomes:
measure: Newly detected AF
timeFrame: during influenza vaccination
Secondary outcomes:
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: General Practices
Study officials:
affiliation: Martini Ziekenhuis Groningen
name: Robert Tieleman, MD PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Julius Center UMC Utrecht
name: Monika Hollander, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kaasenbrood F, Hollander M, Rutten FH, Gerhards LJ, Hoes AW, Tieleman RG. Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination. Europace. 2016 Oct;18(10):1514-1520. doi: 10.1093/europace/euv426. Epub 2016 Feb 6.
Clinical trial NCT01743924: Bioavailability of Chemopreventive and Nutritional Compounds in Broccoli
Official title: Bioavailability of Bioactive Compounds in Broccoli
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Bioavailability
Keywords: Broccoli; Isothiocyanates; Pharmacokinetics; Sulforaphane; Myrosinase
Lead sponsor: Universidad Politécnica de Cartagena
Sponsor class: OTHER
Collaborators: name: Hospital Universitario Reina Sofia de Cordoba
First posted: 2012-12-06
Enrollment: 7
Sex: ALL
Minimum age (years): 22
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SCREENING

Brief summary: The aim of this study was to determine the absorption of isothiocyanates (ITC) after ingestion of kailan-hybrid broccoli through the analysis of the correspondent urinary biomarkers. Furthermore, the effect of cooking (microwave) on the mentioned metabolic fate of these ITC was studied comparing to the uncooked vegetable.

Detailed description: Background Glucosinolates (sulphur-containing compounds) are hydrolyzed by the plant enzyme myrosinase to ITC, which have chemopreventive properties. No information has been reported about the metabolic fate of ITC in the kailan-hybrid broccoli, which physicochemical characteristics could greatly influence that metabolic fate. Previous studies have shown that cooking process of vegetables may vary the human absorption of the correspondent nutritional and bioactive compounds.

Research Methods \& Procedures A cross-over-design study of 7 subjects after ingestion of 200-g raw or microwaved kailan-hybrid broccoli was conducted. Total ITC equivalents in the vegetable, urine and blood samples were determined by HPLC as the cyclocondensation product of 1,2-benzenedithiol.

Eligibility criteria: Inclusion Criteria:

* Subjects with a body mass index between 19 and 28.
* Subjects age: 22-50 years-old.
* Good health of subjects: confirmed by medical history, physical examination and clinical laboratory analysis of urine and blood (complete blood count and liver function markers including serum glutamic-pyruvic transaminase bilirubin test and glucose-6-phosphate dehydrogenase).

Exclusion Criteria:

* Tobacco smoking.
* Use of regular medications.
* Had taken antibiotics for 4 weeks immediately preceding the study.
* History of kidney stones, diabetes mellitus, bleeding disorders or family history of iron overload/hemochromatosis.

Primary outcomes:
measure: Metabolic fate of ITC of the kailan-hybrid broccoli after human comsuption
timeFrame: Up to 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Murcia
country: Spain
facility: Hospital General Universitario Reina Sofía
Study officials:
affiliation: Comité ético de investigación clínica
name: Maria Concepcion Maeztu Sardiña, Doctor
role: STUDY_CHAIR
References:
Clinical trial NCT02958124: Early Mobilization: Evaluation of Feasibility and Security in Pediatric Intensive Care Unit
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cardio-Respiratory Distress
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2016-11-08
Enrollment: 50
Sex: ALL
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients admitted in pediatric intensive care unit that respond to eligibility criteria

Brief summary: The purpose of this study is to evaluate the feasibility and the security of early mobilization of infants in pediatric intensive care.


Eligibility criteria: Inclusion Criteria:

* cardiorespiratory stability
* between 24 and 48h post admission

Exclusion Criteria:

* Thorax open
* ECLS
* High frequency oscillatory ventilation

Primary outcomes:
measure: Respiratory parameters assessed by monitoring
timeFrame: up to 1 hour
Secondary outcomes:
measure: EDIN scale (tool for assessing prolonged pain in preterm and newborns)
timeFrame: 5 minutes before mobilization
measure: EDIN scale (tool for assessing prolonged pain in preterm and newborns)
timeFrame: up to 1 hour
measure: COMFORT-BEHAVIOR scale (to measure the amount of stress of ventilated infants in a pediatric intensive care unit)
timeFrame: 5 minutes before mobilization
measure: COMFORT-BEHAVIOR scale (to measure the amount of stress of ventilated infants in a pediatric intensive care unit)
timeFrame: up to 1 hour
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Cliniques Universitaires Saint Luc
Study officials:
References:
citation: Piva TC, Ferrari RS, Schaan CW. Early mobilization protocols for critically ill pediatric patients: systematic review. Rev Bras Ter Intensiva. 2019 Jun 10;31(2):248-257. doi: 10.5935/0103-507X.20190038.
Clinical trial NCT00931424: The Clinical Trial for Primary Chronic Venous Insufficiency
Official title: The Clinical Research of Surgery on Primary Chronic Venous Insufficiency
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Primary Chronic Venous Insufficiency
Keywords: Primary Chronic Venous Insufficiency
surgery
reconstruction
valve
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2009-07-02
Enrollment: 400
Sex: ALL
Minimum age (years): 15
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A multicenter Random Clinical Trial to confirm the advantage of the valve reconstructive surgery on Primary Chronic Venous Insufficiency.


Eligibility criteria: Inclusion Criteria:

* PCVI patients with III degree back flow in deep vein that is confirmed by color doppler or phlebography

Exclusion Criteria:

* age over 70 years old
* pregnancy
* patients with severity arteriosclerosis obliterans, malignancy, severity disease of heart, lung or brain, and hematopathy

Primary outcomes:
measure: clinical-etiology-anatomic-pathophysiologic classification system
timeFrame: 3 month, 1 year, 3 year, 5 year, 7 year
Secondary outcomes:
measure: phlebography
timeFrame: 3 month, 1 year, 3 year, 5 year, 7 year
measure: color doppler
timeFrame: 3 month, 1 year, 3 year, 5 year, 7 year
Other outcomes:
Locations:
city: Guang Zhou
country: China
facility: The first affiliated hospital of Sun Yat-Sen University
state: Guang dong
Study officials:
affiliation: First Affiliated Hospital, Sun Yat-Sen University
name: Shen-ming Wang, doctor
role: STUDY_CHAIR
References:
Clinical trial NCT00307424: Comparison Between Auto CPAP and Fixed CPAP in Chinese Patients With OSA
Official title: Comparison of Auto-Continuous Positive Airway Pressure Device(Auto-CPAP) With Conventional Fixed CPAP in Chinese Patients With Obstructive Sleep Apnea (OSA)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obstructive Sleep Apnea
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2006-03-28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: AutoCPAP would lead to better compliance than FixCPAP

Detailed description: A prospective, randomized crossover cohort. Study subjects consisted of patients newly diagnosed with obstructive sleep apnea (OSA) confirmed with sleep study. All are CPAP naïve.

Randomization:

Arm 1: auto CPAP sleep study then auto CPAP for 2 months Arm 2: fixed CPAP titration then fixed CPAP for 2 months

Then switch over to the other arm

Trial end after 4 months, compliance and other parameters would be compared between two arms as described in the endpoint session.

Eligibility criteria: Inclusion Criteria:

* All subjects should be CPAP naïve.
* OSA confirmed with sleep study
* Presence of daytime symptoms with excessive daytime sleepiness
* Age between 18 to 65
* RDI greater than 30
* Agreed to participate in trial with informed consent signed

Exclusion Criteria:

* Patients not suitable to nasal CPAP because of facial abnormality leading to poor mask fitting.
* Patients with known COPD with type II failure
* Patients with known heart failure.
* Patients with predominant central sleep apnea.
* Patients need bilevel positive airway pressure ventilation.
* Patients refusing to participate the trial.
* Patients have difficulty to follow up regularly.
* patients with untreated or under treatment of hypothyroidism

Primary outcomes:
measure: To compare the compliance of auto-CPAP and fixed CPAP in terms of CPAP usage hours.
measure: To compare the clinical efficacy of auto-CPAP and fixed CPAP in terms of pressure level to abolish OSA, Epworth sleepiness scale and quality of life questionnaire.
measure: To compare patient acceptance of the different type of treatment.
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: North District Hospital
city: Hong Kong
country: China
facility: Prince of Wales Hospital
Study officials:
affiliation: Prince of Wales Hosptial
name: To K Wang, FHKCP
role: PRINCIPAL_INVESTIGATOR
References:
citation: To KW, Chan WC, Choo KL, Lam WK, Wong KK, Hui DS. A randomized cross-over study of auto-continuous positive airway pressure versus fixed-continuous positive airway pressure in patients with obstructive sleep apnoea. Respirology. 2008 Jan;13(1):79-86. doi: 10.1111/j.1440-1843.2007.01138.x.
Clinical trial NCT06265324: Drug-coated Balloon Treatment in Coronary Lesions
Official title: Immediate and Midterm Clinical Outcome of Drug Coated Balloon Angioplasty in Different Coronary Artery Lesions in Sohag Governorate
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Drug-coated Balloon
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-02-20
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is multicenter registry for drug-coated balloon treatment for de novo and in-stent restenosis lesions

Detailed description: The treatment of coronary lesions triggers processes in vessel walls with different characteristics depending on the revascularization strategy, post-traumatic healing following plain balloon angioplasty triggers vessel recoil and neointimal overgrowth, bare metal or drug eluting stent implantation results in neointimal cell proliferation, scar tissue formation, and ultimately, the generation of neoatherosclerosis Drug-coated balloons(DCBs) were presented two decades ago as an alternative to plain-balloon inﬂation or subsequent stent implantation in order to overcome in-stent restenosis.Recently, there has been growing evidence that DCBs can also be used off-label to treat de novo lesions in small vessels Therefore, the aim of this study is to evaluate efﬁcacy and safety of drug-coated balloons angioplasty for treatment of de novo and in-stent restenosis lesions

Eligibility criteria: Inclusion Criteria:

Eligible patients are those with lesions in the coronary vessel tree who will be planned to be treated with drug coated balloon.

Exclusion Criteria:

1. Severe renal impairment ( Cr.Cl. \< 45 ml/min ).
2. Sever heart failure or liver cell failure .
3. Patients with contraindications to coronary angiography or invasive procedures.
4. Known allergy or intolerance to the medications or devices commonly used during PCI procedures.
5. Severe comorbidities or conditions that may limit life expectancy or impact the ability to follow the study protocol.
6. Pregnant or lactating women.

Primary outcomes:
measure: Major adverse cardiac events at 6 months
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag faculty of medicine
Study officials:
affiliation: Sohag faculty of medicine
name: Sharaf Eldin Shazly, PHD
role: STUDY_DIRECTOR
affiliation: Sohag faculty of medicine
name: Mohammed Abdelwahab, PHD
role: STUDY_CHAIR
affiliation: Sohag faculty of medicine
name: Imran Saber, MA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02240524: Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer
Official title: A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2 Lymphadenectomy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Advanced Gastric Adenocarcinoma
Keywords: Gastric adenocarcinoma
HIPEC
Paclitaxel
Oxaliplatin
Capecitabine
Lead sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Sponsor class: OTHER
First posted: 2014-09-15
Enrollment: 582
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to study the efficacy of hyperthermic intraperitoneal chemotherapy in the treatment of patients with locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy. It is a multicentric and randomised phase III trial.


Eligibility criteria: Inclusion Criteria:

* 18 \< age ≤ 65 years old
* Male or Non pregnant female
* The Eastern Cooperative Oncology Group (ECOG) status ≤ 2
* Histologically diagnosed as T4 gastric adenocarcinoma (determined from data obtained by endoscopic ultrasound or CT scan)
* Have not received cytotoxic chemotherapy, radiotherapy or immunotherapy
* White blood cells \> 4,000/mm3
* neutrophils ≥ 1,500/mm3
* platelets ≥ 100,000/mm3
* hemoglobin\>9g/l
* Alanine transaminase (ALT) and aspartate aminotransferase (AST) \< or = 2.5 times upper limit of nominal (ULN)
* total bilirubin (TBIL) \< 1.5 times ULN
* serum creatinine \< 1 times ULN
* Having given written informed consent prior to any procedure related to the study

Exclusion Criteria:

* Existence of macroscopic peritoneal implants
* Prior malignant tumors with detectable signs of recurrence or distant metastasis
* Poorly controlled disease e.g. atrial fibrillation, stenocardia, cardiac insufficiency, persistent hypertension despite medicinal treatment, ejection fraction\<50%
* Receiving other cytotoxic chemotherapy
* High grade of intra-abdominal adhesions
* Contraindication to any therapy contained in this regimen specific to the study Without given written informed consent

Primary outcomes:
measure: Overall survival
timeFrame: 5 years
Secondary outcomes:
measure: Recurrence-free survival
timeFrame: 5 years
measure: Locoregional-free survival
timeFrame: 5 years
measure: Hepatic metastases-free survival
timeFrame: 5 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical University
state: Guangdong
Study officials:
affiliation: Affiliated Cancer Hospital & Institute of Guangzhou Medical University
name: shuzhong cui, Ph.D
role: STUDY_DIRECTOR
References: